FI
RNAC icon

Fosun International’s Cartesian Therapeutics RNAC Stock Holding History

Fosun International’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,611
Closed -$824K – 281
2019
Q2 		$824K Hold
14,611
– – 0.05% 184
2019
Q1 		$938K Buy
14,611
+8,844
+153% +$561K 0.06% 164
2018
Q4 		$531K Buy
+5,767
New +$1.32M 0.03% 214

Other funds holding RNAC

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Fosun International's RNAC Position: Q3 2019 in Review

Fosun International sold out of Cartesian Therapeutics (RNAC) in Q3 2019, closing a stake of 14,611 shares — an estimated $824K sold.

Fosun International first reported a position in RNAC in Q4 2018 and held it in 3 quarters. The position peaked at $938K in Q1 2019. 36 funds tracked by Wall St. Rank hold RNAC as of Q3 2019.

  • Fosun International reported no remaining Cartesian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 14,611 Cartesian Therapeutics shares in Q3 2019, an estimated $824K.
  • Fosun International first reported a position in Cartesian Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Cartesian Therapeutics position peaked at $938K in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.